Clinical studies should be conducted to investigate whether ARID2 mutations impact the prognosis of HCC patients in general and the prognosis of patients who have undergone treatment (e.g. curative therapy, IFN therapy, etc.). This evidence concerns the gene ARID2 and hepatocellular carcinoma.